



Contents lists available at ScienceDirect

Diagnostic Microbiology and Infectious Disease

journal homepage: www.elsevier.com/locate/diagmicrobio

Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate *Staphylococcus aureus* clinical isolates

Katherine A. Truelson^a, Thea Brennan-Krohn^b, Kenneth P. Smith^b, James E. Kirby^{b,*}

^a Boston University, Boston, MA, USA

^b Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

ARTICLE INFO

Article history:

Received 9 April 2018

Received in revised form 22 May 2018

Accepted 23 May 2018

Available online xxxx

Keywords:

Apramycin

Staphylococcus aureus

Activity spectrum

Repurposing

Antibiotic

Natural product

Synergy

Aminoglycoside

Gentamicin

ABSTRACT

We evaluated the *in vitro* activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible *Staphylococcus aureus*. Apramycin demonstrated an MIC₅₀/MIC₉₀ of 8/16 µg/mL. No strains had an MIC above the epidemiological cutoff value of 32 µg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum *in vitro* activity of apramycin against *S. aureus* and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.

© 2018 Elsevier Inc. All rights reserved.

1. Introduction

Staphylococcus aureus is both a human skin commensal and an opportunistic pathogen. It is the leading cause of bacteremia and infective endocarditis, as well skin and soft tissue, osteoarticular, and surgical site infections (Akhi et al., 2017; Deleo et al., 2010; Tong et al., 2015). Strains resistant to methicillin and by proxy, all β-lactams (so called methicillin resistant *S. aureus* or MRSA), are common in the United States (Tong et al., 2015). Vancomycin is the first-line treatment for methicillin-resistant *S. aureus* (MRSA) infection. However, limitations of vancomycin include relatively lower bactericidal activity compared with β-lactams; nephrotoxicity, associated with high dosages and underlying risk factors; and a requirement for routine monitoring of drug levels to ensure adequate dosing (Hazlewood et al., 2010). Furthermore, vancomycin tolerant and heteroresistant populations may emerge during treatment (Bamberger and Boyd, 2005; Dombrowski and Winston, 2008; Hawkins et al., 2007; Lodise et al., 2008; Steinkraus et al., 2007).

Therefore, additional treatment options for *S. aureus* would be welcome, especially for those strains with resistance to newer agents

such as daptomycin and linezolid. Aminoglycosides are not currently used to treat *S. aureus* infections as single agents. In particular, renal and ototoxic side effects are of significant concern (Jose et al., 2010; Matt et al., 2012). Therefore aminoglycoside therapy is generally reserved for treatment of Gram-negative infection, where pharmacodynamic considerations are considered more favorable (Tam et al., 2006). Currently, gentamicin treatment of *S. aureus* is advocated only in low dose (1 mg/kg q8 h or 3–5 mg/kg q 24 h) in combination with vancomycin or a β-lactam and rifampin, during therapy of staphylococcal endocarditis where prosthetic material is present and in combination with daptomycin for persistent bacteremia (Liu, et al., 2011). However, the relative benefit of gentamicin adjunctive therapy versus risk of kidney damage has been a subject of extensive debate (Bruss, 2009; Buchholtz et al., 2009, 2011; Cosgrove et al., 2009; Frippiat et al., 2009). Therefore, a non-toxic aminoglycoside with predictable activity against *S. aureus* would therefore be especially welcome.

Apramycin is a structurally unique aminoglycoside used in veterinary medicine and is characterized by a bicyclic sugar moiety and a 4-monosubstituted 2-deoxystreptamine ring (Meyer et al., 2014). In contrast to aminoglycosides currently used in human therapy, apramycin appears highly selective for bacterial ribosomes and on this basis thought devoid of significant ototoxic and renal toxic side effects (Matt et al., 2012).

* Corresponding author. Tel.: +1-617-667-3648; fax: +1-617-667-4533.

E-mail address: jkirby@bidmc.harvard.edu. (J.E. Kirby).

Previous data from our group and others have shown broad-spectrum *in vitro* activity of apramycin against carbapenem-resistant Enterobacteriaceae and multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* (Kang et al., 2017; Livermore et al., 2011; Smith and Kirby, 2016a, 2016b). Furthermore, we recently demonstrated potent *in vivo* bactericidal activity against *Acinetobacter baumannii* in a murine thigh infection model (Kang et al., 2018).

However, activity spectrum data for *S. aureus* is limited. Therefore, the goal of this study was to explore *in vitro* activity of apramycin against contemporary clinical isolates of *S. aureus*.

2. Materials and methods

2.1. Bacterial strains and antimicrobials

We evaluated a collection of 109 strains of *S. aureus* for their susceptibility to apramycin. Fourteen *S. aureus* strains obtained from the FDA-CDC Antimicrobial Resistance Isolate Bank (<https://www.cdc.gov/drugresistance/resistance-bank/>) were part of the vancomycin intermediate *S. aureus* panel with vancomycin MIC values of 4–8 µg/mL. Ninety-five additional strains of de-identified *S. aureus* clinical isolates were obtained from the Beth Israel Deaconess Medical Center (Boston, MA) clinical microbiology laboratory. Our strain collection was comprised of 38.5% methicillin-resistant *S. aureus* (MRSA), 48.6% methicillin-susceptible *S. aureus* (MSSA) and 12.9% vancomycin-intermediate *S. aureus* (VISA). All strains were stored frozen at –80 °C in a stock solution of 50% glycerol and 50% cation-adjusted Mueller-Hinton broth (BD Diagnostics, Franklin Lakes, NJ) until use in experiments.

Apramycin sulfate was obtained from Alfa Aesar (Tewksbury, MA) and was dissolved in deionized water at 32 mg/mL and stored at –20 °C in aliquots that were used only once. For synergy studies, apramycin, gentamicin, daptomycin, and vancomycin were dissolved at 100, 100, 10, and 10 mg/mL in water supplemented with 0.3% polysorbate 20 (P-20; Sigma-Aldrich), respectively. Linezolid was dissolved at 30 mg/mL in DMSO (Sigma-Aldrich). Solvents used reflect requirements for liquid handling by the HP D300 Digital Dispensing System (HP Inc., Palo Alto, CA) (Brennan-Krohn et al., 2017; Smith and Kirby, 2016).

2.2. Susceptibility testing

The Clinical Laboratory and Standards Institute (CLSI) broth microdilution reference method was used for MIC testing of apramycin (CLSI, 2015). MIC panels were created by serial dilution of stock apramycin with cation-adjusted Mueller-Hinton broth (BD Diagnostics, Franklin Lakes, NJ) in round bottom, 96-well plates (Evergreen Scientific, Los Angeles, CA). Dilutions were prepared at 2× the final concentration in volumes of 50 µL with final concentrations ranging from 1 to 256 µg/mL after an equal volume of bacterial inoculum (5×10^5 cfu/mL final concentration) was added. Stock solutions were quality controlled against *S. aureus* ATCC 29213 on three separate days. All MIC values for ATCC 29213 were consistently 4 µg/mL, which was in the middle of the 2–8 µg/mL acceptable quality control range suggested by CLSI. Bacterial inocula were prepared by passaging previously frozen bacterial strains on trypticase soy agar containing 5% sheep's blood at 37 °C. Isolated colonies were then suspended in cation-adjusted Mueller-Hinton broth (CAMHB) for a final inoculum concentration of 5×10^5 CFU/mL. After inoculation, broth microdilution plates were incubated at 35 °C in ambient air for 16–20 hours. Each experiment also included both a positive (*S. aureus* ATCC 25923) and a negative control to which no organisms were added. *S. aureus* ATCC 25923 always showed an MIC of 4 or 8 µg/mL supporting consistency of assay readout.

2.3. MIC interpretation

The MIC of each strain from our collection was determined in duplicate on separate days. If duplicate MICs were within one doubling

dilution of each other but were not the same, the higher MIC was used. If duplicate MICs were not within one doubling dilution of each other, a third replicate was performed, and the MIC was defined as the modal MIC of the three replicates. Categorical breakpoints for apramycin are not available either from the CLSI or the European Committee for Antimicrobial Susceptibility Testing and, therefore, categorical interpretation was not performed.

2.4. Time-kill studies

Time-kill studies were performed according to CLSI guidelines (Clinical and Laboratory Standards Institute, 1999). To prepare a starting inoculum for the time-kill studies, 100 µL of a 0.5 McFarland suspension of colonies from an overnight plate was added to 5 mL of CAMHB and incubated on a shaker in ambient air at 35 °C until it reached log phase growth. The log phase culture was then adjusted to a turbidity of 1.0 McFarland in CAMHB, and 100 µL of this suspension was added to 10 mL volumes of antimicrobial solutions in CAMHB at time 0. Antibiotic concentrations selected were based on multiples of each isolate's MIC as determined through broth microdilution assays. A growth control and a negative control were run in parallel with each experiment. Cultures were incubated on a shaker in ambient air at 35 °C.

Aliquots from the culture were removed at 0, 1, 2, 4, 6, and 24 hours. A serial 10-fold dilution in 0.9% sodium chloride was prepared and a 10 µL drop from each dilution was transferred to a Mueller-Hinton plate (Thermo Fisher, Waltham, MA) (Chen et al., 2003; Herigstad et al., 2001; Naghili et al., 2013) and incubated overnight in ambient air at 35 °C. Colonies within each drop were counted. For drops containing 3–30 colonies, the cell density of the sample was calculated; if more than one dilution for a given sample had a countable number of colonies, the cell density of the two dilutions was averaged. If no drops had a countable number of colonies, the two drops above and below the countable range were averaged. The limit of detection was 300 CFU mL^{–1}. Bactericidal activity was defined as a reduction of ≥ 3 log₁₀ CFU mL^{–1} at 24 hours compared to the starting inoculum (Leber, 2016; Pillai et al., 2005).

2.5. Synergy studies

Checkboard synergy arrays consisting of orthogonal two-fold serial dilutions of antibiotic combinations were set up using the HPD300 as previously described (Brennan-Krohn et al., 2017). Combinatorial fractional inhibitory concentrations ≤ 0.5 were considered synergistic; > 0.5 and < 4 were considered indifferent; and ≥ 4 were considered antagonistic (Odds, 2003).

2.6. Statistical analysis

R was used to plot MIC distributions and for statistical analysis (RStudio, 2017; Team, 2017). $P < 0.05$ was considered to be statistically significant.

3. Results

The *S. aureus* collection had a narrow apramycin MIC range of 4 to 32 µg/mL (see Fig. 1). The MIC₅₀ and the MIC₉₀ were 8 µg/mL and 16 µg/mL, respectively. Based on the visual inspection method, an apramycin epidemiological cutoff value of 32 µg/mL was assigned (Turnbridge and Patterson, 2007). A chi-square test of independence detected no significant relationship between MSSA, MRSA and VISA strain phenotype and apramycin MIC distribution ($P = 0.17$).

Apramycin exposure led to rapid killing of clinical MSSA strain S27 and MRSA strain S19 at 1×–4× the broth microdilution MIC in time-kill experiments. However, regrowth was observed between 6 and 24 hours (Fig. 2). In contrast, VISA strain, FDA-CDC AR Bank #226, showed

Download English Version:

<https://daneshyari.com/en/article/8964060>

Download Persian Version:

<https://daneshyari.com/article/8964060>

[Daneshyari.com](https://daneshyari.com)